Literature DB >> 3102718

A pharmacodynamic model for the activity of antibiotics against microorganisms under nonsaturable conditions.

J Zhi, C H Nightingale, R Quintiliani.   

Abstract

An exact mathematical solution was derived to a pharmacodynamic model which illustrates bacterial survival in the presence of antibiotics. In this report the survival of Pseudomonas aeruginosa in the medium of an initial concentration of 0.64 mM (320 mg/L) of piperacillin [(2S,5R,6R)-6-[(R)-2-(4-ethyl-2,3-dioxo-1- piperazinecarboxyamido)-2-phenylacetamido]-3,3-dimethyl-7- oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate] was well described by the derived model for up to 24 h. The bacterial killing by the antibiotic and apparent natural growth rate constants were 2955.3 h-1 X mol-1 and 0.5698 h-1, respectively. The functional equation was also fit to the data of ampicillin against Escherichia coli under simulated in vivo conditions. The optimal multiple dosing time and the minimum critical concentration to achieve antimicrobial action can be readily calculated from the developed model. Computer simulations were made to examine the effect on microbial survival of such factors as initial antibiotic concentration (Co), elimination half-life (t1/2), kill rate constant (K) of the antibiotic, and apparent growth rate constant (Kapp) of the test organism.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3102718     DOI: 10.1002/jps.2600751108

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  22 in total

1.  Pharmacokinetic/pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine.

Authors:  Pierre-Louis Toutain
Journal:  AAPS PharmSci       Date:  2002

2.  Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens.

Authors:  Roland R Regoes; Camilla Wiuff; Renata M Zappala; Kim N Garner; Fernando Baquero; Bruce R Levin
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

3.  Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments.

Authors:  Elisabet I Nielsen; Anders Viberg; Elisabeth Löwdin; Otto Cars; Mats O Karlsson; Marie Sandström
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

4.  Simultaneous pharmacodynamic analysis of the lag and bactericidal phases exhibited by beta-lactams against Escherichia coli.

Authors:  R C Li
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

5.  Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model.

Authors:  A A Firsov; S N Vostrov; A A Shevchenko; G Cornaglia
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

6.  Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion.

Authors:  J W Mouton; A A Vinks; N C Punt
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

7.  Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization.

Authors:  Elisabet I Nielsen; Otto Cars; Lena E Friberg
Journal:  Antimicrob Agents Chemother       Date:  2011-08-01       Impact factor: 5.191

8.  Pharmacodynamics of non-replicating viruses, bacteriocins and lysins.

Authors:  James J Bull; Roland R Regoes
Journal:  Proc Biol Sci       Date:  2006-11-07       Impact factor: 5.349

9.  Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo.

Authors:  Johan W Mouton; Nieko Punt; Alexander A Vinks
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

10.  Antimicrobial breakpoint estimation accounting for variability in pharmacokinetics.

Authors:  Goue Denis Gohore Bi; Jun Li; Fahima Nekka
Journal:  Theor Biol Med Model       Date:  2009-06-26       Impact factor: 2.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.